Published in TB and Outbreaks Week, March 9th, 2004
In response to this threat, ImmuneRegen BioSciences, a wholly owned subsidiary of IR Biosciences Holdings, Inc., (IRBH) recently completed testing on the Hong Kong influenza virus, which is similar to that of SARS and the avian flu.
Company executives believe this research may indicate efficacy of their proprietary compound, Homspera, in treating the Hong Kong respiratory virus in mice. Additionally, company executives believe these test results are vital to research...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.